Exagen Secures $75 Million Credit Agreement

An update from Exagen ( (XGN) ) is now available.

On April 25, 2025, Exagen Inc. entered into a Credit Agreement with Perceptive Credit Holdings IV, LP, securing a senior secured delayed draw term loan facility of up to $75 million, with an initial $25 million tranche funded to refinance existing debt and extend the maturity. This strategic financial move is aimed at strengthening Exagen’s balance sheet and providing growth capital, allowing the company to further its leadership in autoimmune testing solutions and enhance patient care. The agreement includes additional tranches contingent on revenue and business development milestones, with the loan secured by Exagen’s assets and accompanied by a warrant to purchase shares of Exagen’s common stock.

Spark’s Take on XGN Stock

According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.

Exagen’s stock is moderately attractive with a score of 56. Key strengths include record revenue growth and strategic advancements highlighted in the earnings call, which anticipate positive adjusted EBITDA. However, ongoing net losses, negative cash flows, and valuation challenges dampen the outlook. Improvements in financial stability and achieving profitability are critical for enhancing the stock’s attractiveness.

To see Spark’s full report on XGN stock, click here.

More about Exagen

Exagen Inc. is a leading provider of autoimmune diagnostics based in San Diego County, California. The company is committed to transforming care for patients with chronic autoimmune conditions through its innovative testing portfolio. Its flagship product, AVISE® CTD, aids in the diagnosis of complex autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren’s syndrome.

YTD Price Performance: 100.97%

Average Trading Volume: 119,549

Technical Sentiment Signal: Sell

Current Market Cap: $111.1M

For an in-depth examination of XGN stock, go to TipRanks’ Stock Analysis page.